The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heckelsmiller, K.
Right arrow Articles by Hartmann, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heckelsmiller, K.
Right arrow Articles by Hartmann, G.
The Journal of Immunology, 2002, 169: 3892-3899.
Copyright © 2002 by The American Association of Immunologists

Peritumoral CpG DNA Elicits a Coordinated Response of CD8 T Cells and Innate Effectors to Cure Established Tumors in a Murine Colon Carcinoma Model1

Klaus Heckelsmiller, Katharina Rall, Sebastian Beck, Angelika Schlamp, Julia Seiderer, Bernd Jahrsdörfer, Anne Krug, Simon Rothenfusser, Stefan Endres and Gunther Hartmann2

Department of Internal Medicine, Division of Clinical Pharmacology, University of Munich, Munich, Germany

The immune system of vertebrates is able to detect bacterial DNA based on the presence of unmethylated CpG motifs. We examined the therapeutic potential of oligodeoxynucleotides with CpG motifs (CpG ODN) in a colon carcinoma model in BALB/c mice. Tumors were induced by s.c. injection of syngeneic C26 cells or Renca kidney cancer cells as a control. Injection of CpG ODN alone or in combination with irradiated tumor cells did not protect mice against subsequent tumor challenge. In contrast, weekly injections of CpG ODN into the margin of already established tumors resulted in regression of tumors and complete cure of mice. The injection site was critical, since injection of CpG ODN at distant sites was not effective. Mice with two bilateral C26 tumors rejected both tumors upon peritumoral injection of one tumor, indicating the development of a systemic immune response. The tumor specificity of the immune response was demonstrated in mice bearing a C26 tumor and a Renca tumor at the same time. Mice that rejected a tumor upon peritumoral CpG treatment remained tumor free and were protected against rechallenge with the same tumor cells, but not with the other tumor, demonstrating long term memory. Tumor-specific CD8 T cells as well as innate effector cells contributed to the antitumor activity of treatment. In conclusion, peritumoral CpG ODN monotherapy elicits a strong CD8 T cell response and innate effector mechanisms that seem to act in concert to overcome unresponsiveness of the immune system toward a growing tumor.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
W. N. Haining, J. Davies, H. Kanzler, L. Drury, T. Brenn, J. Evans, J. Angelosanto, S. Rivoli, K. Russell, S. George, et al.
CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans
Clin. Cancer Res., September 1, 2008; 14(17): 5626 - 5634.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Nierkens, M. H. den Brok, R. P.M. Sutmuller, O. M. Grauer, E. Bennink, M. E. Morgan, C. G. Figdor, T. J.M. Ruers, and G. J. Adema
In vivo Colocalization of Antigen and Cytidyl Guanosyl within Dendritic Cells Is Associated with the Efficacy of Cancer Immunotherapy
Cancer Res., July 1, 2008; 68(13): 5390 - 5396.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. H.M.G.M. den Brok, R. P.M. Sutmuller, S. Nierkens, E. J. Bennink, L. W.J. Toonen, C. G. Figdor, T. J.M. Ruers, and G. J. Adema
Synergy between In situ Cryoablation and TLR9 Stimulation Results in a Highly Effective In vivo Dendritic Cell Vaccine.
Cancer Res., July 15, 2006; 66(14): 7285 - 7292.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Tormo, A. Ferrer, P. Bosch, E. Gaffal, E. Basner-Tschakarjan, J. Wenzel, and T. Tuting
Therapeutic Efficacy of Antigen-Specific Vaccination and Toll-Like Receptor Stimulation against Established Transplanted and Autochthonous Melanoma in Mice.
Cancer Res., May 15, 2006; 66(10): 5427 - 5435.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Chaperot, A. Blum, O. Manches, G. Lui, J. Angel, J.-P. Molens, and J. Plumas
Virus or TLR Agonists Induce TRAIL-Mediated Cytotoxic Activity of Plasmacytoid Dendritic Cells
J. Immunol., January 1, 2006; 176(1): 248 - 255.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Avogadri, C. Martinoli, L. Petrovska, C. Chiodoni, P. Transidico, V. Bronte, R. Longhi, M. P. Colombo, G. Dougan, and M. Rescigno
Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor Cells
Cancer Res., May 1, 2005; 65(9): 3920 - 3927.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Guiducci, A. P. Vicari, S. Sangaletti, G. Trinchieri, and M. P. Colombo
Redirecting In vivo Elicited Tumor Infiltrating Macrophages and Dendritic Cells towards Tumor Rejection
Cancer Res., April 15, 2005; 65(8): 3437 - 3446.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Jahrsdorfer, L. Muhlenhoff, S. E. Blackwell, M. Wagner, H. Poeck, E. Hartmann, R. Jox, T. Giese, B. Emmerich, S. Endres, et al.
B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides
Clin. Cancer Res., February 15, 2005; 11(4): 1490 - 1499.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Chagnon, S. Tanguay, O. L. Ozdal, M. Guan, Z. Z. Ozen, J.-S. Ripeau, M. Chevrette, M. M. Elhilali, and L. A. Thompson-Snipes
Potentiation of a Dendritic Cell Vaccine for Murine Renal Cell Carcinoma by CpG Oligonucleotides
Clin. Cancer Res., February 1, 2005; 11(3): 1302 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. A. Mason, H. Ariga, R. Neal, D. Valdecanas, N. Hunter, A. M. Krieg, J. K. Whisnant, and L. Milas
Targeting Toll-like Receptor 9 with CpG Oligodeoxynucleotides Enhances Tumor Response to Fractionated Radiotherapy
Clin. Cancer Res., January 1, 2005; 11(1): 361 - 369.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Hiraoka, S. Yamamoto, S. Otsuru, S. Nakai, K. Tamai, R. Morishita, T. Ogihara, and Y. Kaneda
Enhanced Tumor-Specific Long-Term Immunity of Hemaggluttinating Virus of Japan-Mediated Dendritic Cell-Tumor Fused Cell Vaccination by Coadministration with CpG Oligodeoxynucleotides
J. Immunol., October 1, 2004; 173(7): 4297 - 4307.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Milas, K. A. Mason, H. Ariga, N. Hunter, R. Neal, D. Valdecanas, A. M. Krieg, and J. K. Whisnant
CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation
Cancer Res., August 1, 2004; 64(15): 5074 - 5077.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. J. Kemp, J. M. Moore, and T. S. Griffith
Human B Cells Express Functional TRAIL/Apo-2 Ligand after CpG-Containing Oligodeoxynucleotide Stimulation
J. Immunol., July 15, 2004; 173(2): 892 - 899.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Switaj, A. Jalili, A. B. Jakubowska, N. Drela, M. Stoksik, D. Nowis, G. Basak, J. Golab, P. J. Wysocki, A. Mackiewicz, et al.
CpG Immunostimulatory Oligodeoxynucleotide 1826 Enhances Antitumor Effect of Interleukin 12 Gene-Modified Tumor Vaccine in a Melanoma Model in Mice
Clin. Cancer Res., June 15, 2004; 10(12): 4165 - 4175.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Garbi, B. Arnold, S. Gordon, G. J. Hammerling, and R. Ganss
CpG Motifs as Proinflammatory Factors Render Autochthonous Tumors Permissive for Infiltration and Destruction
J. Immunol., May 15, 2004; 172(10): 5861 - 5869.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
A. Vogt, P.-T. Chuang, J. Hebert, J. Hwang, Y. Lu, L. Kopelovich, M. Athar, D. R. Bickers, and E. H. Epstein Jr.
Immunoprevention of Basal Cell Carcinomas with Recombinant Hedgehog-interacting Protein
J. Exp. Med., March 15, 2004; 199(6): 753 - 761.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Rothenfusser, V. Hornung, M. Ayyoub, S. Britsch, A. Towarowski, A. Krug, A. Sarris, N. Lubenow, D. Speiser, S. Endres, et al.
CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro
Blood, March 15, 2004; 103(6): 2162 - 2169.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Chaput, N. E. C. Schartz, F. Andre, J. Taieb, S. Novault, P. Bonnaventure, N. Aubert, J. Bernard, F. Lemonnier, M. Merad, et al.
Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection
J. Immunol., February 15, 2004; 172(4): 2137 - 2146.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Hartmann, B. Wollenberg, S. Rothenfusser, M. Wagner, D. Wellisch, B. Mack, T. Giese, O. Gires, S. Endres, and G. Hartmann
Identification and Functional Analysis of Tumor-Infiltrating Plasmacytoid Dendritic Cells in Head and Neck Cancer
Cancer Res., October 1, 2003; 63(19): 6478 - 6487.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. J. Kemp, B. D. Elzey, and T. S. Griffith
Plasmacytoid Dendritic Cell-Derived IFN-{alpha} Induces TNF-Related Apoptosis-Inducing Ligand/Apo-2L-Mediated Antitumor Activity by Human Monocytes Following CpG Oligodeoxynucleotide Stimulation
J. Immunol., July 1, 2003; 171(1): 212 - 218.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Krishnan, S. Sad, G. B. Patel, and G. D. Sprott
Archaeosomes Induce Enhanced Cytotoxic T Lymphocyte Responses to Entrapped Soluble Protein in the Absence of Interleukin 12 and Protect against Tumor Challenge
Cancer Res., May 15, 2003; 63(10): 2526 - 2534.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.